Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [06/13/2025 07:01 PDT] sector Stocks Expected To Be Down After Top Correlated Stocks Fire Sell Signals.
• [05/27/2025 10:29 PDT] Savara Inc. (NASDAQ:SVRA), Down By 100% ($2.99) From $2.99 After BUYINS.NET Report Predicted Stock Would Go Down Due To Bearish Conditions
• [05/27/2025 10:29 PDT] Savara Inc. (NASDAQ:SVRA), Down By 100% ($3) From $3 After BUYINS.NET Report Predicted Stock Would Go Down Due To Bearish Conditions
• [05/23/2025 07:52 PDT] sector Stocks Expected To Be Down After Top Correlated Stocks Fire Sell Signals.
• [05/15/2025 13:20 PDT] SVRA SqueezeTrigger Price is $0.00. There is $0 That Short Sellers Still Need To Cover.
• [05/12/2025 10:29 PDT] SVRA SqueezeTrigger Price is $0.00. There is $0 That Short Sellers Still Need To Cover.
• [05/07/2025 08:16 PDT] SVRA SqueezeTrigger Price is $0.00. There is $0 That Short Sellers Still Need To Cover.
• [05/07/2025 06:54 PDT] SVRA Expected to Trade Down After Bearish Patterns Develop